Current insight on trends, causes, and mechanisms of Hodgkin's lymphoma

Cancer Journal

Volumn 15, Issue 2, 2009, Pages 117-123

  Caporaso, Neil E ^a   Goldin, Lynn R ^a   Anderson, William F ^a   Landgren, Ola ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Epidemiology; Etiology; Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; AUTOIMMUNE DISEASE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; HEREDITY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INFECTIOUS MONONUCLEOSIS; LIFESTYLE; PATHOGENESIS; PRIORITY JOURNAL; REED STERNBERG CELL; REVIEW; RISK FACTOR; VIRUS ETIOLOGY;

EUROPE; HODGKIN DISEASE; HUMANS; INCIDENCE; RISK FACTORS; UNITED STATES;

EID: 68149124711     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181a39585     Document Type: Review

References (117)

1. Hodgkin T. On some morbid experiences of the absorbent glands and spleen. Med Chir Trans. 1832;17:69-97.
2. Wilks S. Cases of enlargement of the lymphatic glands and spleen (or Hodgkin's disease), with remarks. Guy's Hosp Rep. 1865;11:56-67.
3. Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid tissues. Lyon: IARC Press; 2001.
4. Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents. Vol.I-VIII. IARC CancerBase No. 7. Lyon: International Agency for Research on Cancer (IARC); 2005.
5. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute; 2006.
6. O'Grady J, Stewart S, Elton RA, et al. Epstein-Barr virus in Hodgkin's disease and site of origin of tumour. Lancet. 1994;343:265-266. (Pubitemid 24039628)
7. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virusnegative Hodgkin's lymphoma. Lancet. 2005;365:2216-2224. (Pubitemid 40853915)
8. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108:3786-3791.
9. Bierman PJ, Vose JM, Langnas AN, et al. Hodgkin's disease following solid organ transplantation. Ann Oncol. 1996;7:265-270. (Pubitemid 26129397)
10. Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol. 1999;17:3122-3127. (Pubitemid 29470641)
11. Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst. 2006;98:1321-1330. (Pubitemid 44530727)
12. Goldgar DE, Easton DF, Cannon-Albright LA, et al. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86:1600-1608.
13. Goldin LR, Pfeiffer RM, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer. 2004;100:1902-1908. (Pubitemid 38529568)
14. Lindelof B, Eklund G. Analysis of hereditary component of cancer by use of a familial index by site. Lancet. 2001;358:1696-1698. (Pubitemid 33124331)
15. Paltiel O, Schmit T, Adler B, et al. The incidence of lymphoma in first-degree relatives of patients with Hodgkin's disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study. Cancer. 2000;88:2357-2366. (Pubitemid 30247137)
16. Shugart YY, Hemminki K, Vaittinen P, et al. A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. Hum Genet. 2000;106:553-556. (Pubitemid 30406682)
17. Westergaard T, Melbye M, Pedersen JB, et al. Birth order, sibship size and risk of Hodgkin's disease in children and young adults: a population-based study of 31 million person-years. Int J Cancer. 1997;72:977-981. (Pubitemid 27433561)
18. Au WY, Gascoyne RD, Gallagher RE, et al. Hodgkin's lymphoma in Chinese migrants to British Columbia: a 25-year survey. Ann Oncol. 2004;15:626-630.
19. Seow A, Koh WP, Chia KS, et al. Trends In Cancer Incidence in Singapore 1968-2002, 6. Singapore: Singapore Cancer Registry; 2004.
20. Jackson J, Parker J. Hodgkin's Disease and Allied Disorders. New York: Oxford University Press; 1947.
21. Harris NL. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol. 1999;36:220-232. (Pubitemid 29360214)
22. Smetana HF, Cohen BM. Mortality in relation to histologic type in Hodgkin's disease. Blood. 1956;11:211-224.
23. Rosenthal S. Significance of tissue lymphocytes in the prognosis of lymphogranulomatosis. Arch Path. 1936;21:628-646.
24. Lukes RJ. Relationship of histologic features to clinical stages in Hodgkin's disease. Am J Roentgenol Radium Ther Nucl Med. 1963;90:944-955.
25. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063-1083.
26. Harris NL, Jaffe ES, Diebold J, et al. Lymphoma classification - from controversy to consensus: the R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol, 2000;11 (Suppl 1):3-10. (Pubitemid 30111858)
27. Cossman J, Annunziata CM, Barash S, et al. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood. 1999;94:411-416. (Pubitemid 29323854)
28. Brauninger A, Hansmann ML, Strickler JG, et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med. 1999;340:1239-1247. (Pubitemid 29181644)
29. Kuppers R, Roers A, Kanzler H. Molecular single cell studies of normal and transformed lymphocytes. Cancer Surv. 1997;30:45-58. (Pubitemid 27371535)
30. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453-458. (Pubitemid 27333046)
31. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95:1443-1450. (Pubitemid 30099859)
32. Braeuninger A, Kuppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A. 1997;94:9337-9342. (Pubitemid 27357830)
33. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood. 2002;99:409-426. (Pubitemid 34533074)
34. Carbone A, Gloghini A, Gaidano G, et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood. 1998;92:2220-2228. (Pubitemid 28452961)
35. Falini B, Bigerna B, Pasqualucci L, et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood. 1996;87:465-471. (Pubitemid 26030301)
36. Muschen M, Rajewsky K, Brauninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000;191:387-394. (Pubitemid 30060928)
37. Seitz V, Hummel M, Marafioti T, et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood. 2000;95:3020-3024. (Pubitemid 30321149)
38. Anonymous. Cancer Facts & Figures 2007. Atlanta: American Cancer Society; 2007.
39. Perkins CI, Morris CR, Wright WE, et al. Cancer Incidence and Mortality in California by Detailed Race/Ethnicity, 1988-1992. Sacramento, CA: California Department of Health Services Surveillance Section; 1995.
40. Kennedy BJ, Fremgen AM, Menck HR. The National Cancer Data Base report on Hodgkin's disease for 1985-1989 and 1990-1994. Cancer. 1998;83:1041-1047.
41. Duggan DB, Petroni GR, Johnson JL, et al. A. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003;21:607-614.
42. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-1484.
43. Diehl V, Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)? Cancer Invest. 2006;24:713-717. (Pubitemid 44836175)
44. Forsyth PD, Bessell EM, Moloney AJ, et al. Hodgkin's disease in patients older than 70 years of age: a registry-based analysis. Eur J Cancer. 1997;33:1638-1642. (Pubitemid 28123487)
45. Eghbali H, Hoerni-Simon G, de Mascarel I, et al. Hodgkin's disease in the elderly. A series of 30 patients aged older than 70 years. Cancer. 1984;53:2191-2193. (Pubitemid 14101794)
46. Wedelin C, Bjorkholm M, Biberfeld P, et al. Prognostic factors in Hodgkin's disease with special reference to age. Cancer. 1984;53:1202-1208. (Pubitemid 14196505)
47. Landgren O. Diagnostic and Prognostic Studies in Hodgkin's Lymphoma. Stockholm: Karolinska Institutet; 2002:54.
48. Westling P. Studies of the prognosis in Hodgkin's disease. Acta Radiol. 1965;245 (Suppl):5-125.
49. Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88:438-444. (Pubitemid 36547130)
50. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23:5052-5060. (Pubitemid 46224012)
51. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16:124-131. (Pubitemid 40124489)
52. Weekes CD, Vose JM, Lynch JC, et al. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol. 2002;20:1087-1093. (Pubitemid 34141854)
53. Proctor SJ, White J, Jones GL. An international approach to the treatment of Hodgkin's disease in the elderly: launch of the SHIELD study programme. Eur J Haematol Suppl. 2005;63-67. (Pubitemid 40873980)
54. Landgren O, Axdorph U, Fears TR, et al. A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients. Ann Oncol. 2006;17:1290-1295. (Pubitemid 44288220)
55. van Spronsen DJ, Janssen-Heijnen ML, Breed WP, et al. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol. 1999;78:315-319.
56. Erdkamp FL, Breed WP, Bosch LJ, et al. Hodgkin disease in the elderly. A registry-based analysis. Cancer. 1992;70:830-834.
57. Peterson BA, Pajak TF, Cooper MR, et al. Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep. 1982;66:889-898.
58. Levis A, Depaoli L, Bertini M, et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica. 1996;81:450-456. (Pubitemid 126506574)
59. Specht L, Nissen NI. Hodgkin's disease and age. Eur J Haematol. 1989;43:127-135.
60. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park). 2008;22:1369 -1379; discussion 1379, 1385, 1388-1393.
61. Correa P, O'Conor GT. Epidemiologic patterns of Hodgkin's disease. Int J Cancer. 1971;8:192-201.
62. Macfarlane GJ, Evstifeeva T, Boyle P, et al. International patterns in the occurrence of Hodgkin's disease in children and young adult males. Int J Cancer. 1995;61:165-169.
63. Aozasa K, Ueda T, Tamai M, et al. Hodgkin's disease in Osaka, Japan (1964 -1985). Eur J Cancer Clin Oncol. 1986;22:1117-1119.
64. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100:1989-1996. (Pubitemid 35001228)
65. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484-3494. (Pubitemid 34894682)
66. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101-2108. (Pubitemid 34408801)
67. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431-3439. (Pubitemid 46603515)
68. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997;8(Suppl 1):115-118.
69. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465-475. (Pubitemid 37430500)
70. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95:971-980. (Pubitemid 36896714)
71. Hill DA, Gilbert E, Dores GM, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. 2005;106:3358-3365. (Pubitemid 41609165)
72. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428-1437. (Pubitemid 41520078)
73. Foss Abrahamsen A, Andersen A, Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol. 2002;13:1786-1791. (Pubitemid 35439459)
74. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-1886. (Pubitemid 46348183)
75. Hjalgrim H, Askling J, Sorensen P, et al. Risk of Hodgkin's disease and other cancers after infectious mononucleosis. J Natl Cancer Inst. 2000;92:1522-1528. (Pubitemid 30757426)
76. Lehtinen T, Lumio J, Dillner J, et al. Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies - a prospective study. Cancer Causes Control. 1993;4:187-193. (Pubitemid 23149532)
77. Mueller N, Mohar A, Evans A, et al. Epstein-Barr virus antibody patterns preceding the diagnosis of non-Hodgkin's lymphoma. Int J Cancer. 1991;49:387-393.
78. Mueller NE. Hodgkin's disease. In: Schottenfield D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press; 1996:893-919.
79. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70:375-382.
80. Flavell KJ, Biddulph JP, Powell JE, et al. South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease. Br J Cancer. 2001;85:350-356.
81. Tomita Y, Ohsawa M, Kanno H, et al. Epstein-Barr virus in Hodgkin's disease patients in Japan. Cancer. 1996;77:186-192. (Pubitemid 26002756)
82. Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer. 2000;82:1117-1121. (Pubitemid 30128866)
83. Sleckman BG, Mauch PM, Ambinder RF, et al. Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection. Cancer Epidemiol Biomarkers Prev. 1998;7:1117-1121.
84. Gallagher A, Perry J, Freeland J, et al. Hodgkin's lymphoma and Epstein-Barr virus (EBV): no evidence to support hit-and-run mechanism in cases classified as non-EBV-associated. Int J Cancer. 2003;104:624-630.
85. Benharroch D, Shemer-Avni Y, Levy A, et al. New candidate virus in association with Hodgkin's disease. Leuk Lymphoma. 2003;44:605-610. (Pubitemid 36304817)
86. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351:1833-1839.
87. Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol. 2005;130:662-670.
88. Klippel JH. Primer on the Rheumatic Diseases. Atlanta: Arthritis Foundation; 2001.
89. Bjornadal L, Lofstrom B, Yin L, et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002;31:66-71. (Pubitemid 34518083)
90. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888-892.
91. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31:691-696.
92. Mellemkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:761-768. (Pubitemid 27157584)
93. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993;85:307-311. (Pubitemid 23068804)
94. Ekstrom K, Hjalgrim H, Brandt L, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 2003;48:963-970. (Pubitemid 36418238)
95. Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497-502. (Pubitemid 30747077)
96. Mellemkjaer L, Alexander F, Olsen JH. Cancer among children of parents with autoimmune diseases. Br J Cancer. 2000;82:1353-1357. (Pubitemid 30145358)
97. Hartge P, Wang SS, eds. Overview of the Etiology and Epidemiology of Lymphoma. Non-Hodgkin's Lymphoma. Philadelphia: Lippincott Williams & Wilkins, 2004.
98. Landgren O, Kerstann KF, Gridley G, et al. Re: Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst. 2005;97:543-544.
99. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51-60. (Pubitemid 43057092)
100. Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol. 2005;162:1153-1161.
101. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337-2344. (Pubitemid 41640845)
102. Penn I. Neoplastic complications of transplantation. Semin Respir Infect. 1993;8:233-239.
103. Haluska FG, Brufsky AM, Canellos GP. The cellular biology of the Reed-Sternberg cell. Blood. 1994;84:1005-1019.
104. Garnier JL, Lebranchu Y, Lefrancois N, et al. Hodgkin's disease after renal transplantation. Transplant Proc. 1995;27:1785.
105. Goldin LR, McMaster ML, Ter-Minassian M, et al. A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. J Med Genet. 2005;42:595-601. (Pubitemid 40993837)
106. Cordano P, Lake A, Shield L, et al. Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol. 2005;128:493-495. (Pubitemid 40283166)
107. Cozen W, Gebregziabher M, Conti DV, et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev. 2006;15:2285-2291. (Pubitemid 44883053)
108. Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood. 2004;103:3216-3221. (Pubitemid 38451701)
109. Glaser SL. Reproductive factors in Hodgkin's disease in women: a review. Am J Epidemiol. 1994;139:237-246. (Pubitemid 24062760)
110. Kravdal O, Hansen S. The importance of childbearing for Hodgkin's disease: new evidence from incidence and mortality models. Int J Epidemiol. 1996;25:737-743. (Pubitemid 26290055)
111. Kravdal O, Hansen S. Hodgkin's disease: the protective effect of childbearing. Int J Cancer. 1993;55:909-914. (Pubitemid 24005333)
112. Swerdlow A, dos Santos Silva I, Doll R. Cancer Incidence and Mortality in England and Wales: Trends and Risk Factors. Oxford: Oxford University Press; 2001.
113. McCunney RJ. Hodgkin's disease, work, and the environment. A review. J Occup Environ Med. 1999;41:36-46.
114. Grufferman NM. Hodgkin's lymphoma. In: David Schottenfeld J, Joseph F. Fraumeni, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press; 2006:872-897.
115. SEER-13: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 13 Regs Limited-Use, Nov 2007 Sub (1973-2005) 〈Single Ages to 85+, Katrinia/Rita Population Adjustment〉 -Linked To County Attributes - Total U.S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on November 2007 submission, 2008.
116. SEER-17: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 17 Regs Limited-Use, Nov 2007 Sub (1973-2005) 〈Single Ages to 85+, Katrinia/Rita Population Adjustment〉 -Linked To County Attributes - Total U.S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on November 2007 submission, 2008.
117. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002, Cancer Incidence, Mortality and Prevalence Worldwide, IARC CancerBase No. 5, version 2.0. Lyon, France, IARC Press, 2004.